SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Guggenheim Maintains Buy Rating on Genmab, Raises Target to $80

Guggenheim maintained its Buy rating on Genmab and raised its price target to $80 from $58.

GMAB

Related stories